Table 3.
Median OS (intent-to-treat) and PFS (intent-to-treat)
| ID DSP-7888 n = 10 |
SC DSP-7888 n = 14 |
Overall (N = 24) |
||||
|---|---|---|---|---|---|---|
| 3.5 mg (n = 4) |
10.5 mg (n = 3) |
17.5 mg (n = 3) |
3.5 mg (n = 9) |
10.5 mg (n = 5) |
||
| Median OS, days (95% CI) | 176.0 (NE–NE) | NE (182.0–NE) | 220.0 (117.0–494.0) | 311.0 (97.0–311.0) | 103.0 (42.0–180.0) | 180.0 (136.0–494.0) |
| Median PFS, days (95% CI) | 51.0 (33.0–56.0) | 62.0 (52.0–66.0) | 54.0 (29.0–NE) | 48.5 (12.0–57.0) | 77.0 (33.0–103.0) | 52.0 (41.0–57.0) |
CI confidence interval, ID intradermal, NE not evaluable, OS overall survival, PFS progression-free survival, SC subcutaneous